Gastrointestinal Infections News

Patients with recurrent Clostridioides difficile infection on average avoided 17 days of hospitalization in the first year after being treated with fecal microbiota transplantation, according to real-world data.

ATLANTA — Contaminated asparagus was the likely source of a large outbreak of shigellosis at a wedding party in Oregon that sickened 112 people, according to findings presented at the CDC’s Epidemic Intelligence Service, or EIS, conference.

The FDA approved Mavyret to treat all six genotypes of hepatitis C in pediatric patients aged 12 years to 17 years, according to a press release from the organization.

While fecal microbiota transplantation has long been established as a treatment for adult patients with Clostridioides difficile infection, data from a study revealed that it is also safe and effective in pediatric patients.

VIENNA — In this exclusive video from the International Liver Congress 2019, Philippa Easterbrook, MD, senior scientist of the Global Hepatitis Program within the HIV Department at the WHO headquarters in Geneva, Switzerland, discusses the future of direct-acting antiviral access for children and adolescents with hepatitis C.

VIENNA — In this exclusive video from the International Liver Congress 2019, Olufunmilayo Lesi, FWACP, FMCP, from the University of Lagos in Nigeria, discusses the WHO’s goal for global elimination of viral hepatitis by the year 2030.

Study findings showed that hospital transfers cause a “minority but substantial burden” of Clostridioides difficile infections in California and that the burden could be reduced by 13% statewide if contamination from hospital transfers was eliminated.

The FDA approved revisions to the Viread product labeling to include safety and pregnancy-related outcome data from three published trials in pregnant women with chronic hepatitis B.

The incidence of most foodborne infections increased last year in the United States, according to newly published data from the Foodborne Diseases Active Surveillance Network, or FoodNet.

VIENNA — In this exclusive video from the International Liver Congress 2019, James Merson, PhD, global therapeutic area head for infectious diseases at Janssen, discusses the company’s pipeline for hepatitis B with a focus on improving functional cure rates.